Literature DB >> 21700659

A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion.

Salvatore P Mangiafico1, Shueh H Lim, Sandra Neoh, Helene Massinet, Christos N Joannides, Joseph Proietto, Sofianos Andrikopoulos, Barbara C Fam.   

Abstract

Increased glucose production is associated with fasting hyperglycaemia in type 2 diabetes but whether or not it causes glucose intolerance is unclear. This study sought to determine whether a primary defect in gluconeogenesis (GNG) resulting in elevated glucose production is sufficient to induce glucose intolerance in the absence of insulin resistance and impaired insulin secretion. Progression of glucose intolerance was assessed in phosphoenolpyruvate carboxykinase (PEPCK) transgenic rats, a genetic model with a primary increase in GNG. Young (4-5 weeks of age) and adult (12-14 weeks of age) PEPCK transgenic and Piebald Virol Glaxo (PVG/c) control rats were studied. GNG, insulin sensitivity, insulin secretion and glucose tolerance were assessed by intraperitoneal and intravascular substrate tolerance tests and hyperinsulinaemic/euglycaemic clamps. Despite elevated GNG and increased glucose appearance, PEPCK transgenic rats displayed normal glucose tolerance due to adequate glucose disposal and robust glucose-mediated insulin secretion. Glucose intolerance only became apparent in the PEPCK transgenic rats following the development of insulin resistance (both hepatic and peripheral) and defective glucose-mediated insulin secretion. Taken together, a single genetic defect in GNG leading to increased glucose production does not adversely affect glucose tolerance. Insulin resistance and impaired glucose-mediated insulin secretion are required to precipitate glucose intolerance in a setting of chronic glucose oversupply.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700659     DOI: 10.1530/JOE-11-0126

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  4 in total

1.  Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.

Authors:  Carolina E Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Barbara C Fam; Henrik Ortsäter; Pierre Scotney; Daniel Nyqvist; Erik Samén; Li Lu; Sharon Stone-Elander; Joseph Proietto; Sofianos Andrikopoulos; Ake Sjöholm; Andrew Nash; Ulf Eriksson
Journal:  Nature       Date:  2012-09-26       Impact factor: 49.962

2.  Loss of growth hormone-mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity.

Authors:  Yash Chhabra; Caroline N Nelson; Monika Plescher; Johanna L Barclay; Aaron G Smith; Sof Andrikopoulos; Salvatore Mangiafico; David J Waxman; Andrew J Brooks; Michael J Waters
Journal:  FASEB J       Date:  2019-02-19       Impact factor: 5.191

3.  The role of liver fructose-1,6-bisphosphatase in regulating appetite and adiposity.

Authors:  Sherley Visinoni; Nurul Fathiah Izzati Khalid; Christos N Joannides; Arthur Shulkes; Mildred Yim; Jon Whitehead; Tony Tiganis; Benjamin J Lamont; Jenny M Favaloro; Joseph Proietto; Sofianos Andrikopoulos; Barbara C Fam
Journal:  Diabetes       Date:  2012-05       Impact factor: 9.461

Review 4.  EndMT Regulation by Small RNAs in Diabetes-Associated Fibrotic Conditions: Potential Link With Oxidative Stress.

Authors:  Roberta Giordo; Yusra M A Ahmed; Hilda Allam; Salah Abusnana; Lucia Pappalardo; Gheyath K Nasrallah; Arduino Aleksander Mangoni; Gianfranco Pintus
Journal:  Front Cell Dev Biol       Date:  2021-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.